Glucowatch to be given expedited review:
This article was originally published in Clinica
The US FDA will review Cygnus' premarket approval (PMA) application for the GlucoWatch automatic, non-invasive glucose monitor under expedited review status. This is given to technology which is seen as in the public's health interest and therefore a priority for approval. Redwood City, California-based Cygnus submitted the final module of its PMA last month (see Clinica No 861, p 17).
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.